Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52.

View in: PubMed

subject areas

Administration, Oral
Aged
Antineoplastic Agents
Benzimidazoles
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Mutation
Neoplasm Metastasis
Quinolones
Receptor, Fibroblast Growth Factor, Type 3
Treatment Outcome
Urologic Neoplasms

authors with profiles

Walter M. Stadler